Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Bullone, Michela ^a   Vargas, Amandine ^a   Elce, Yvonne ^a,c   Martin, James G ^b   Lavoie, Jean Pierre ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BRONCHODILATING AGENT; FLUTICASONE; SALMETEROL XINAFOATE;

ADOLESCENT; AIRWAY REMODELING; ANIMAL; ASTHMA; CHILD; DISEASE EXACERBATION; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMALE; HORSE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; SEVERITY OF ILLNESS INDEX; SMOOTH MUSCLE; YOUNG ADULT;

ADOLESCENT; AIRWAY REMODELING; ANIMALS; ANTIGENS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; FLUTICASONE; HORSES; HUMANS; MALE; MUSCLE, SMOOTH; NEUTROPHIL INFILTRATION; NEUTROPHILS; SALMETEROL XINAFOATE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85027837260     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09414-8     Document Type: Article

References (67)

1. Bergeron, C., Tulic, M. K. & Hamid, Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 17, e85-93 (2010).
2. Grainge, C. L. et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364, 2006-2015, doi:10.1056/NEJMoa1014350 (2011).
3. James, A. L. et al. Airway smooth muscle thickness in asthma is related to severity but not duration of asthma. Eur Respir J 34, 1040-1045 (2009).
4. James, A. L. et al. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med 185, 1058-1064, doi:10.1164/rccm.201110-1849OC (2012).
5. Lambert, R. K., Wiggs, B. R., Kuwano, K., Hogg, J. C. & Pare, P. D. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol 74, 2771-2781 (1993).
6. Poon, A. H., Eidelman, D. H., Martin, J. G., Laprise, C. & Hamid, Q. Pathogenesis of severe asthma. Clin Exp Allergy 42, 625-637, doi:10.1111/j.1365-2222.2012.03983.x (2012).
7. Woodruff, P. G. & Innes, A. L. Quantitative morphology using bronchial biopsies. Eur Respir Rev 15, 157-161, doi:10.1183/09059180.00010106 (2006).
8. Carroll, N., Elliot, J., Morton, A. & James, A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 147, 405-410 (1993).
9. Manoharan, A., Anderson, W. J., Lipworth, J., Ibrahim, I. & Lipworth, B. J. Small airway dysfunction is associated with poorer asthma control. Eur Respir J 44, 1353-1355, doi:10.1183/09031936.00082314 (2014).
10. Farah, C. S. et al. Association between peripheral airway function and neutrophilic inflammation in asthma. Respirology 20, 975-981, doi:10.1111/resp.12550 (2015).
11. Black, J. L., Oliver, B. G. & Roth, M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists. Chest 136, 1095-1100, doi:10.1378/chest.09-0354 (2009).
12. GINA Guidelines, Global Strategy for Asthma Management and Prevention, (2016).
13. Anderson, W. J., Zajda, E. & Lipworth, B. J. Are we overlooking persistent small airways dysfunction in community-managed asthma? Ann Allergy Asthma Immunol 109, 185-189 e182, doi:10.1016/j.anai.2012.06.022 (2012).
14. Bergeron, C. et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 116, 983-989, doi:10.1016/j.jaci.2005.07.029 (2005).
15. Postma, D. S. et al. Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. Eur Respir J 45, 1534-1538, doi:10.1183/09031936.00214314 (2015).
16. Balzar, S., Wenzel, S. E. & Chu, H. W. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 20, 254-259 (2002).
17. Leclere, M., Lavoie-Lamoureux, A. & Lavoie, J. P. Heaves, an asthma-like disease of horses. Respirology 16, 1027-1046, doi:10.1111/j.1440-1843.2011.02033.x (2011).
18. Bullone, M., Godbout, M., Martin, G. J. & Lavoie, J. P. Endobronchial ultrasonography of isolated bronchi reveals increased airway smooth muscle mass in large airways of asthmatic horses. Am J Respir Crit Care Med 189, A2382 (2014).
19. Bullone, M., Chevigny, M., Allano, M., Martin, J. G. & Lavoie, J. P. Technical and physiological determinants of airway smooth muscle mass in endobronchial biopsy samples of asthmatic horses. J Appl Physiol (1985) 117, 806-815, doi:10.1152/japplphysiol.00468.2014 (2014).
20. Leclere, M., Bedard, C., Cortes-Dubly, M. L. & Lavoie, J. P. Blood hypercoagulability and systemic inflammation in horses with heaves. Veterinary Journal 206, 105-107, doi:10.1016/j.tvjl.2015.04.012 (2015).
21. Abraham, G., Brodde, O. E. & Ungemach, F. R. Regulation of equine lymphocyte beta-adrenoceptors under the influence of clenbuterol and dexamethasone. Equine Vet J 34, 587-593 (2002).
22. Herszberg, B., Ramos-Barbon, D., Tamaoka, M., Martin, J. G. & Lavoie, J. P. Heaves, an asthma-like equine disease, involves airway smooth muscle remodeling. J Allergy Clin Immunol 118, 382-388, doi:10.1016/j.jaci.2006.03.044 (2006).
23. Leclere, M. et al. Effect of antigenic exposure on airway smooth muscle remodeling in an equine model of chronic asthma. Am J Respir Cell Mol Biol 45, 181-187, doi:10.1165/rcmb.2010-0300OC (2011).
24. Leclere, M. et al. Corticosteroids and Antigen Avoidance Decrease Airway Smooth Muscle Mass in an Equine Asthma Model. Am J Respir Cell Mol Biol, 589-596, doi:10.1165/rcmb.2011-0363OC (2012).
25. Bullone, M., Beauchamp, G., Godbout, M., Martin, J. G. & Lavoie, J. P. Endobronchial Ultrasound Reliably Quantifies Airway Smooth Muscle Remodeling in an Equine Asthma Model. PLoS One 10, e0136284, doi:10.1371/journal.pone.0136284 (2015).
26. Reid, D. W. et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 21, 994-999 (2003).
27. Jeffery, P. K. et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20, 1378-1385 (2002).
28. Maneechotesuwan, K. et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128, 1936-1942, doi:10.1378/chest.128.4.1936 (2005).
29. Monteseirin, J. Neutrophils and asthma. J Investig Allergol Clin Immunol 19, 340-354 (2009).
30. Holgate, S. T. et al. Epithelial-mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac Soc 1, 93-98, doi:10.1513/pats.2306034 (2004).
31. Chernyavsky, I. L. et al. The role of inflammation resolution speed in airway smooth muscle mass accumulation in asthma: insight from a theoretical model. PLoS One 9, e90162, doi:10.1371/journal.pone.0090162 (2014).
32. Hamid, Q. et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 100, 44-51 (1997).
33. Wenzel, S. E. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156, 737-743, doi:10.1164/ajrccm.156.3.9610046 (1997).
34. Roth, M. et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360, 1293-1299, doi:10.1016/S0140-6736(02)11319-5 (2002).
35. Yick, C. Y. et al. Glucocorticoid-induced changes in gene expression of airway smooth muscle in patients with asthma. Am J Respir Crit Care Med 187, 1076-1084, doi:10.1164/rccm.201210-1886OC (2013).
36. Chevigny, M., Guerin-Montpetit, K., Vargas, A., Lefebvre-Lavoie, J. & Lavoie, J. P. Contribution of SRF, Elk-1, and myocardin to airway smooth muscle remodeling in heaves, an asthma-like disease of horses. Am J Physiol Lung Cell Mol Physiol 309, L37-45, doi:10.1152/ajplung.00050.2015 (2015).
37. Vargas, A., Roux-Dalvai, F., Droit, A. & Lavoie, J. P. Neutrophil-Derived Exosomes: A New Mechanism Contributing to Airway Smooth Muscle Remodeling. Am J Respir Cell Mol Biol 55, 450-461, doi:10.1165/rcmb.2016-0033OC (2016).
38. Qian, C. J., Coulombe, J., Suissa, S. & Ernst, P. Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. Br J Clin Pharmacol, doi:10.1111/bcp.13295 (2017).
39. Manuyakorn, W. et al. Mechanical Strain Causes Adaptive Change in Bronchial Fibroblasts Enhancing Profibrotic and Inflammatory Responses. PLoS One 11, e0153926, doi:10.1371/journal.pone.0153926 (2016).
40. Kotaru, C. et al. Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med 173, 1208-1215, doi:10.1164/rccm.200508-1218OC (2006).
41. Chakir, J. et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 111, 1293-1298 (2003).
42. Bosse, Y., Riesenfeld, E. P., Pare, P. D. & Irvin, C. G. It's not all smooth muscle: non-smooth-muscle elements in control of resistance to airflow. Annu Rev Physiol 72, 437-462, doi:10.1146/annurev-physiol-021909-135851 (2010).
43. Araujo, B. B. et al. Extracellular matrix components and regulators in the airway smooth muscle in asthma. Eur Respir J 32, 61-69, doi:10.1183/09031936.00147807 (2008).
44. Yick, C. Y. et al. Extracellular matrix in airway smooth muscle is associated with dynamics of airway function in asthma. Allergy 67, 552-559, doi:10.1111/j.1398-9995.2011.02773.x (2012).
45. Nihlberg, K. et al. Altered matrix production in the distal airways of individuals with asthma. Thorax 65, 670-676, doi:10.1136/thx.2009.129320 (2010).
46. Pini, L. et al. Differences in proteoglycan deposition in the airways of moderate and severe asthmatics. Eur Respir J 29, 71-77, doi:10.1183/09031936.00047905 (2007).
47. Lambers, C. et al. Extracellular matrix composition is modified by beta(2)-agonists through cAMP in COPD. Biochem Pharmacol 91, 400-408, doi:10.1016/j.bcp.2014.07.026 (2014).
48. Lamyel, F. et al. The beta2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn Schmiedebergs Arch Pharmacol 384, 133-145, doi:10.1007/s00210-011-0655-5 (2011).
49. Levenson, M. Long-acting beta-agonists and adverse asthma events meta-analysis statistical briefing package for joint meeting of the pulmonary-allergy drugs advisory committee, drug safety and risk management advisory committee and pediatric advisory committee on December 10-11, 2008. Quantitative safety and pharmacoepidemiology group, United States Food and Drug Administration. (2008).
50. Boulet, L. P. et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 11, 1091-1097 (1998).
51. Cheung, D. et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327, 1198-1203, doi:10.1056/NEJM199210223271703 (1992).
52. Knight, J. M. et al. Long-Acting Beta Agonists Enhance Allergic Airway Disease. PLoS One 10, e0142212, doi:10.1371/journal. pone.0142212 (2015).
53. Kamachi, A. et al. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 56, 19-24 (2001).
54. Riesenfeld, E. P. et al. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res 11, 22, doi:10.1186/1465-9921-11-22 (2010).
55. Bai, T. R., Vonk, J. M., Postma, D. S. & Boezen, H. M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 30, 452-456, doi:10.1183/09031936.00165106 (2007).
56. O'Byrne, P. M. et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179, 19-24, doi:10.1164/rccm.200807-1126OC (2009).
57. Ogawa, H., Fujimura, M., Takeuchi, Y. & Makimura, K. Impact of Schizophyllum sensitization on decline of lung function in asthma. J Asthma 50, 764-768, doi:10.3109/02770903.2013.803573 (2013).
58. Dijkstra, A. et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61, 105-110, doi:10.1136/thx.2004.039271 (2006).
59. Lange, P., Scharling, H., Ulrik, C. S. & Vestbo, J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 61, 100-104, doi:10.1136/thx.2004.037978 (2006).
60. Henrikson, S. L. & Rush, B. R. Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction. J Am Vet Med Assoc 218, 1961-1965 (2001).
61. Jean, D., Vrins, A. & Lavoie, J. P. Monthly, daily, and circadian variations of measurements of pulmonary mechanics in horses with chronic obstructive pulmonary disease. Am J Vet Res 60, 1341-1346 (1999).
62. Derksen, F. J. et al. Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. Am J Vet Res 60, 689-693 (1999).
63. Couetil, L. et al. Effects of N-butylscopolammonium bromide on lung function in horses with recurrent airway obstruction. J Vet Intern Med 26, 1433-1438, doi:10.1111/j.1939-1676.2012.00992.x (2012).
64. Jean, D., Vrins, A., Beauchamp, G. & Lavoie, J. P. Evaluation of variations in bronchoalveolar lavage fluid in horses with recurrent airway obstruction. Am J Vet Res 72, 838-842, doi:10.2460/ajvr.72.6.838 (2011).
65. Lugo, J. et al. Safety and efficacy of a technique for thoracoscopically guided pulmonary wedge resection in horses. Am J Vet Res 63, 1232-1240 (2002).
66. Relave, F. et al. Thoracoscopic lung biopsies in heaves-affected horses using a bipolar tissue sealing system. Vet Surg 39, 839-846, doi:10.1111/j.1532-950X.2010.00720.x (2010).
67. Russell, H. K. Jr. A modification of Movat's pentachrome stain. Arch Pathol 94, 187-191 (1972).